Search filters

Filters

Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 118
  • 386
  • 179
  • 13
  • 19
  • 354
  • 381
  • 5
  • 4
  • 382

Found 386 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

PALLAS: PALbociclib CoLlaborative Adjuvant Study

18 years - 99 years
All genders
Phase 3
The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.
Learn More
UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

18 years - 99 years
All genders
Phase 2
This study tests the safety and effectiveness of the combination of ublituximab, umbralisib, and venetoclax. Patients with Chronic Lymphocytic Leukemia (CLL) will be invited to participate in this trial.
Learn More
A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

19 years - 99 years
All genders
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs
Learn More
A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Interventional
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
Learn More
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
Learn More

ONC-108

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

Test 20260407-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

Test 20260407-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

Test 20260612

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

Test 20260612-1

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More
141 - 150 of 386